Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Idarucizumab: The Antidote for Reversal of Dabigatran.

× No keyword cloud information.

29 in total

1. The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors: Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal: P T Date: 2017-11

Review 2. Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors: Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal: Drug Deliv Transl Res Date: 2018-08 Impact factor: 4.617

3. Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update.

Authors: Manuel Cappellari; Stefano Forlivesi; Giovanna Maddalena Squintani; Roberto Facchinetti; Paolo Bovi
Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300

Review 4. New Oral Anticoagulants and Their Reversal Agents.

Authors: Andrea Morotti; Joshua N Goldstein
Journal: Curr Treat Options Neurol Date: 2016-11 Impact factor: 3.598

5. Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".

Authors: Kirollos S Kamel; Paul K L Chin; Matthew P Doogue; Murray L Barclay
Journal: Clin Pharmacokinet Date: 2017-02 Impact factor: 6.447

6. Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis.

Authors: Satoshi Hosoki; Masahito Takagi; Hiroshi Yamagami; Daisuke Ando; Kazunori Toyoda; Masatoshi Koga
Journal: J Neurol Date: 2018-08-16 Impact factor: 4.849

Review 7. Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

Authors: Antoni Martínez-Rubio; Mario DiazNuila Alcazar; Anna Soria Cadena; Roger Martínez-Torrecilla
Journal: Eur Cardiol Date: 2016-12

Idarucizumab: The Antidote for Reversal of Dabigatran.